Type 1 diabetes: UAB startup gains FDA clearance to test novel oral drug

By: Emma Shepard

The University of Alabama at Birmingham startup TIXiMED Inc. has received clearance from the U.S. Food and Drug Administration to proceed to clinical trials under an Investigational New Drug for TIX100, its novel oral Type 1 diabetes drug. This represents a major milestone in the development of this new approach to T1D treatment and gives TIXiMED the green light to start human studies with TIX100.

The development of TIX100 is based on decades of research by Dr. Anath Shalev, the Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Juvenile Diabetes Research in the UAB Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine and the director of the UAB Comprehensive Diabetes Center.

“Since TIX100 is available orally, it promises to ease the burden of the multiple daily insulin injections or insulin infusions people with T1D depend on,” Shalev said. “We are so excited to see our work being translated into a better diabetes treatment that may impact so many people and provide a breakthrough for T1D.”

The Alabama Weather Blog is pleased to present an excerpt from a featured article in partnership with the Alabama News Center. For the full post including images, videos, and related links, please visit the article HERE.

Category: ALL POSTS, Partner News Stories